A functional mini-GDE transgene corrects impairment in models of glycogen storage disease type III
Journal of Clinical Investigation · 16.01.2024 · 134 (2)
DOI: 10.1172/jci172018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 16.01.2024. Verfasst von Antoine Gardin und 21 weiteren Autor:innen. Beteiligte Einrichtung: Genethon, Evry, France. Hauptthemen laut MEDLINE: Glycogen Storage Disease Type III, Glycogen Debranching Enzyme System. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: French National Research Agency, CALMIP center.
Abstract (Originalsprache)
Glycogen storage disease type III (GSDIII) is a rare inborn error of metabolism affecting liver, skeletal muscle, and heart due to mutations of the AGL gene encoding for the glycogen debranching enzyme (GDE). No curative treatment exists for GSDIII. The 4.6 kb GDE cDNA represents the major technical challenge toward the development of a single recombinant adeno-associated virus-derived (rAAV-derived) vector gene therapy strategy. Using information on GDE structure and molecular modeling, we generated multiple truncated GDEs. Among them, an N-terminal-truncated mutant, ΔNter2-GDE, had a similar efficacy in vivo compared with the full-size enzyme. A rAAV vector expressing ΔNter2-GDE allowed significant glycogen reduction in heart and muscle of Agl-/- mice 3 months after i.v. injection, as well as normalization of histology features and restoration of muscle strength. Similarly, glycogen accumulation and histological features were corrected in a recently generated Agl-/- rat model. Finally, transduction with rAAV vectors encoding ΔNter2-GDE corrected glycogen accumulation in an in vitro human skeletal muscle cellular model of GSDIII. In conclusion, our results demonstrated the ability of a single rAAV vector expressing a functional mini-GDE transgene to correct the muscle and heart phenotype in multiple models of GSDIII, supporting its clinical translation to patients with GSDIII.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genethon, Evry, France.
- Université Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare research unit UMR_S951, Evry, France.
- CECS, I-STEM, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases, Corbeil-Essonnes, France.
- Toulouse Biotechnology Institute, TBI, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, France.
Förderung
- French National Research Agency
- CALMIP center
Zitieren
APA
Gardin, A., Rouillon, J., Montalvo-Romeral, V., Rossiaud, L., Vidal, P., Launay, R., Vie, M., Krimi Benchekroun, Y., Cosette, J., Bertin, B., La Bella, T., Dubreuil, G., Nozi, J., Jauze, L., Fragnoud, R., Daniele, N., Van Wittenberghe, L., Esque, J., André, I., …, & Ronzitti, G. (2024). A functional mini-GDE transgene corrects impairment in models of glycogen storage disease type III. Journal of Clinical Investigation, 134(2). https://doi.org/10.1172/jci172018
Vancouver
Gardin A, Rouillon J, Montalvo-Romeral V, Rossiaud L, Vidal P, Launay R, et al. A functional mini-GDE transgene corrects impairment in models of glycogen storage disease type III. Journal of Clinical Investigation. 2024;134(2). doi:10.1172/jci172018
BibTeX
@article{Gardin2024,
author = {Gardin, Antoine and Rouillon, Jérémy and Montalvo-Romeral, Valle and Rossiaud, Lucille and Vidal, Patrice and Launay, Romain and Vie, Mallaury and Krimi Benchekroun, Youssef and Cosette, Jérémie and Bertin, Bérangère and La Bella, Tiziana and Dubreuil, Guillaume and Nozi, Justine and Jauze, Louisa and Fragnoud, Romain and Daniele, Nathalie and Van Wittenberghe, Laetitia and Esque, Jérémy and André, Isabelle and Nissan, Xavier and Hoch, Lucile and Ronzitti, Giuseppe},
title = {A functional mini-GDE transgene corrects impairment in models of glycogen storage disease type III},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {2},
doi = {10.1172/jci172018}
}
EUVIMED